Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference Accessibility Statement Skip Navigation Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven’s proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale… Continue reading Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Tag: Morgan
Kipu Introduces the First Intelligent Operating System for Behavioral Healthcare Industry
New Kipu Helix Platform and Kipu Circle Partner Ecosystem unveiled during JPM Week MIAMI, Jan. 12, 2026 /PRNewswire/ — Kipu Health, the leading technology platform for behavioral healthcare, today announced significant company momentum driven by strong customer growth, national scale, partner ecosystem growth and the launch of Kipu Helix, Kipu’s new intelligent operating system purpose-built for behavioral… Continue reading Kipu Introduces the First Intelligent Operating System for Behavioral Healthcare Industry
Field Medical présentera un exposé lors de la 44e conférence annuelle J.P. Conférence Morgan Healthcare
CARDIFF-BY-THE-SEA, Calif., 12 janvier 2026 /PRNewswire/ — Field Medical Inc. est une société de technologie médicale au stade clinique qui développe une plateforme d’ablation par champ pulsé (PFA) polyvalente de nouvelle génération conçue pour prendre en charge l’ablation de la tachycardie ventriculaire (TV) et de la fibrillation auriculaire (FA), et a annoncé aujourd’hui que son… Continue reading Field Medical présentera un exposé lors de la 44e conférence annuelle J.P. Conférence Morgan Healthcare
Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ — Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on… Continue reading Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
Field Medical präsentiert auf der 44. jährlichen J.P. Morgan Healthcare-Konferenz
CARDIFF-BY-THE-SEA, Kalifornien, 12. Januar 2026 /PRNewswire/ — Field Medical Inc., ein Medizintechnikunternehmen im klinischen Stadium, das eine vielseitige Plattform der nächsten Generation für die gepulste Feldablation (PFA) entwickelt hat, die sowohl die Ablation von ventrikulären Tachykardien (VT) als auch von Vorhofflimmern (AF) unterstützt, gab heute bekannt, dass sein Gründer, Steven Mickelsen, MD, auf dem 44.… Continue reading Field Medical präsentiert auf der 44. jährlichen J.P. Morgan Healthcare-Konferenz
Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies
Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of corporate growth Kainova champions scientific agility, bold ambition, and unity of purpose MONTREAL, STRASBOURG, France and BOSTON, Jan. 12, 2026 /PRNewswire/ — Kainova Therapeutics (“Kainova” or “the Company”), a catalyst for breakthrough treatments for patients in immuno-oncology and inflammation, today announced a transformative rebrand. The… Continue reading Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies
Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
SHANGHAI and BOSTON, Jan. 11, 2026 /PRNewswire/ — Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15th 2026 at… Continue reading Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed by planned BLA filing, mid-year Expecting FDA PDUFA decision and multiple pivotal top-line data readouts in 2026 to support potential commercial launches 2026-2028 In-house manufacturing and… Continue reading REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025. Preliminary, Unaudited Select Fourth Quarter 2025 Financial Results Revenue of approximately $166.0 million for the three months ended… Continue reading 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026. The company will review these updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at… Continue reading IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference